🔍

TARSONS - Tarsons Products

📊 NSE: TARSONS 🏢 Miscellaneous 📅 Last Updated: 12/14/2025 14:08

📢 Recent Corporate Announcements

Tarsons Appoints Mani Kalyan Dusi as Head of Revenue for India & APAC

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 14 Apr 2026, 06:40 PM

Tarsons Products Limited has appointed Mr. Mani Kalyan Dusi as the Head of Revenue for India and the APAC region, effective on or before May 20, 2026. Mr. Dusi joins with over 18 years of experience in the life sciences and pharmaceutical sectors, having held senior roles at global giants like Merck Life Science and Thermo-Fisher Scientific. His expertise in commercial leadership and go-to-market strategies is expected to drive growth in key regional markets. This appointment strengthens the company's senior management team as it looks to expand its footprint in the APAC region.

Mr. Mani Kalyan Dusi appointed as Head - Revenue (India & APAC) starting May 20, 2026
Brings over 18 years of experience from industry leaders Merck Life Science and Thermo-Fisher Scientific
Expertise includes P&L management, strategic marketing, and digital enablement in the life sciences sector
Educational background includes an M.Sc. in Biochemistry and executive education from INSEAD
The role is designated as Senior Management Personnel (SMP) to lead regional business development

💡 Investors should view this as a positive step in professionalizing management and strengthening commercial capabilities. Monitor the company's revenue growth in the APAC region over the next 4-6 quarters to assess the impact of this leadership change.

Tarsons Products Submits SEBI Compliance Certificate for Quarter Ended March 31, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 09 Apr 2026, 06:09 PM

Tarsons Products Limited has filed its quarterly compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018. The certificate, provided by KFin Technologies Limited, confirms that the details of securities dematerialized or rematerialized during the quarter ended March 31, 2026, have been furnished to the stock exchanges. This is a standard administrative filing required for all listed companies to ensure the reconciliation of share records with depositories like NSDL and CDSL. The announcement does not contain any material financial information or changes to business operations.

Compliance certificate submitted for the quarter ended March 31, 2026.
Issued by Registrar and Share Transfer Agent (RTA) M/s. KFin Technologies Limited.
Confirms adherence to SEBI (Depositories and Participants) Regulations, 2018.
Covers reporting requirements for both National Securities Depository Limited (NSDL) and Central Depository Services (India) Limited (CDSL).

💡 No action is required from investors as this is a routine regulatory filing. Investors should monitor the company for upcoming financial results or material business developments.

Tarsons Products Infuses EUR 300,000 in Singapore Subsidiary for Debt Servicing

🟡 NEUTRAL ⭐ 6/10

EXPANSION 📅 09 Apr 2026, 05:47 PM

Tarsons Products Limited has completed an equity investment of EUR 300,000 in its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd. This transaction is part of a larger EUR 3,000,000 capital infusion plan previously approved by the Board in February 2026. The funds are specifically allocated for quarterly bank loan repayments, interest payments, and general corporate purposes within the subsidiary. The Singapore entity is a non-operating financial holding company and has reported zero turnover since its incorporation in November 2023.

Completed equity infusion of EUR 300,000 by subscribing to 100 shares at EUR 3,000 each.
Part of a total board-approved investment limit of EUR 3,000,000 for the Singapore subsidiary.
Funds utilized for quarterly repayment of bank loans and interest obligations in Singapore.
The subsidiary, Tarsons Life Science Pte. Ltd., functions as an SPV with nil turnover for FY 2025-26.
The investment ensures the subsidiary meets its financial and operational expenses without change in ownership.

💡 Investors should view this as a routine financial management move to service international debt obligations. Monitor the company's consolidated debt levels and the performance of any assets held under this Singapore SPV.

Tarsons Products Promoter Confirms Zero New Share Encumbrances for FY 2025-26

🟢 POSITIVE ⭐ 4/10

ROUTINE 📅 08 Apr 2026, 05:59 PM

Sanjive Sehgal, the Promoter and CMD of Tarsons Products Limited, has issued a formal declaration under SEBI Takeover Regulations for the financial year ended March 31, 2026. The Promoter and Promoter Group collectively hold 2,51,67,955 equity shares in the company. Crucially, the disclosure confirms that no new encumbrances or pledges were created on these shares, directly or indirectly, during the fiscal year. This routine annual filing provides transparency regarding the stability of the promoter's equity stake.

Promoter and Promoter Group hold 2,51,67,955 equity shares as of March 31, 2026
Declaration submitted under Regulation 31(4) of SEBI (SAST) Regulations, 2011
Confirmed no new encumbrances were made during the financial year 2025-26
Disclosure filed by Sanjive Sehgal, Promoter and Chairman & Managing Director

💡 Investors should take this as a sign of stability in promoter holding and financial health, as there is no new pledging of shares. No immediate portfolio action is required based on this routine compliance filing.

Tarsons Products Appoints M&A Expert Vinesh Mohan Kriplani as Independent Director for 5-Year Term

🟢 POSITIVE ⭐ 6/10

MANAGEMENT 📅 08 Apr 2026, 05:08 PM

Tarsons Products Limited has confirmed the appointment of Mr. Vinesh Mohan Kriplani as a Non-Executive Independent Director for a five-year term, effective February 06, 2026, following shareholder approval. Mr. Kriplani is a seasoned professional with over 29 years of experience in corporate taxation and M&A, currently leading these functions at the Serum Institute of India. His background includes senior leadership roles at Big Four firms like EY, KPMG, and PwC, where he specialized in cross-border transactions and strategic growth. This appointment is expected to significantly bolster the company's board-level expertise in governance and financial strategy.

Appointment of Mr. Vinesh Mohan Kriplani as Non-Executive Independent Director for a 5-year term.
Mr. Kriplani brings over 29 years of experience in international taxation, M&A, and corporate restructuring.
He currently leads M&A and international tax matters for the Poonawalla Group through the Serum Institute of India.
The appointment was ratified by shareholders via postal ballot with the results declared on April 08, 2026.
Mr. Kriplani previously served as a Senior Partner at EY India and is a co-founder of Transaction Square LLP.

💡 Investors should view this as a positive development for corporate governance and strategic oversight. The addition of an M&A and tax specialist from a major healthcare group may indicate a focus on future inorganic growth or complex international expansions.

Tarsons Products Shareholders Approve Appointment of Vinesh Mohan Kriplani as Independent Director

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 08 Apr 2026, 04:59 PM

Tarsons Products Limited has announced the successful passage of a special resolution via postal ballot for the appointment of Mr. Vinesh Mohan Kriplani as a Non-Executive Independent Director. The resolution received overwhelming support, with 99.98% of the 3.78 crore votes cast in favor. The voting process, which concluded on April 6, 2026, saw a total participation rate of 71.15% of the company's share capital. This appointment is part of the company's efforts to maintain regulatory compliance and strengthen board oversight.

Special resolution passed for the appointment of Mr. Vinesh Mohan Kriplani as Non-Executive Independent Director.
Total votes polled were 3,78,53,830, representing 71.15% of the total outstanding shares.
The resolution received 99.98% approval (3,78,48,203 votes) with only 0.01% (5,627 votes) against.
Promoter and Institutional categories showed 100% support for the resolution among those who voted.

💡 This is a routine governance update and requires no immediate action. Investors should continue to monitor the company's operational performance and any strategic shifts resulting from board changes.

Tarsons Products Announces Trading Window Closure from April 1, 2026

🟡 NEUTRAL ⭐ 2/10

ROUTINE 📅 24 Mar 2026, 03:26 PM

Tarsons Products Limited has informed the stock exchanges that its trading window will be closed starting April 1, 2026, for all designated persons and their immediate relatives. This closure is in compliance with SEBI (Prohibition of Insider Trading) Regulations, 2015, ahead of the declaration of audited financial results for the quarter and financial year ending March 31, 2026. The window will remain closed until 48 hours after the financial results are disseminated. The specific date for the board meeting to approve these results will be announced at a later date.

Trading window closure effective from April 1, 2026, for Q4 and FY26 results.
Restriction applies to all Designated Persons and their immediate relatives as per SEBI norms.
Window to reopen 48 hours after the announcement of audited standalone and consolidated results.
Board meeting date for result consideration to be intimated in due course.

💡 This is a routine regulatory announcement with no impact on company fundamentals. Investors should monitor for the upcoming board meeting date to assess the Q4 and FY26 financial performance.

Tarsons Products Seeks Shareholder Approval for Independent Director Appointment for 5-Year Term

🟡 NEUTRAL ⭐ 4/10

MANAGEMENT 📅 06 Mar 2026, 03:55 PM

Tarsons Products Limited has issued a postal ballot notice to seek shareholder approval for the appointment of Mr. Vinesh Mohan Kriplani as a Non-Executive Independent Director. The proposed appointment is for a five-year term effective from February 6, 2026, through February 5, 2031. Shareholders can cast their votes via a remote e-voting process that runs from March 7, 2026, to April 6, 2026. This appointment is being proposed as a Special Resolution to comply with SEBI Listing Regulations and the Companies Act.

Appointment of Mr. Vinesh Mohan Kriplani as Non-Executive Independent Director for a 5-year tenure.
The proposed term runs from February 6, 2026, to February 5, 2031.
Remote e-voting period is set for 30 days, starting March 7 and ending April 6, 2026.
The cut-off date for determining shareholder voting eligibility was February 27, 2026.
The resolution requires approval as a Special Resolution via postal ballot.

💡 Investors should review the director's credentials in the explanatory statement to ensure the board's composition remains robust. This is a routine governance matter and does not require any change in investment strategy.

Tarsons Products Q3 FY26: Revenue Up 12.8%, Adjusted Cash PAT Surges 38.6% YoY

🟢 POSITIVE ⭐ 8/10

EARNINGS 📅 11 Feb 2026, 05:41 PM

Tarsons Products reported a consolidated revenue of ‑108 crores for Q3 FY26, a 12.8% YoY growth, while adjusted cash PAT rose significantly by 38.6% to ‑31.4 crores. Reported PAT was impacted by higher depreciation of ‑60.6 crores for 9M FY26 following the partial capitalization of the Panchla facility. Management highlighted a revenue potential of over ‑150 crores from the new bioprocess container line at full capacity. With cell culture capex expected to commercialize in Q4 FY26, the company anticipates stronger revenue momentum in FY27.

Consolidated revenue grew 12.8% YoY to ‑108 crores in Q3 FY26.
Adjusted Cash PAT increased by 38.6% YoY to ‑31.4 crores, reflecting strong operational performance.
Standalone EBITDA margin stood at 34.7%, while consolidated EBITDA margin was 29.2%.
New bioprocess container capacity has a potential revenue generation of ‑150+ crores at full utilization.
Depreciation increased to ‑60.6 crores for 9M FY26 due to the ‑600 crore Panchla facility expansion.

💡 Investors should monitor the ramp-up of the Panchla facility and the adoption of new cell culture products in FY27. Focus on Cash PAT and EBITDA as primary metrics while the company navigates high depreciation from its major capex cycle.

Tarsons Products to Meet Institutional Investors on February 16, 2026

🟡 NEUTRAL ⭐ 3/10

ROUTINE 📅 10 Feb 2026, 04:56 PM

Tarsons Products Limited has scheduled an investor and analyst meeting for February 16, 2026, in Mumbai. The event, hosted by Spark Capital, will feature both group and one-on-one meeting formats starting from 10:00 A.M. IST. The company has stated that the discussions will be based strictly on publicly available information, ensuring no unpublished price sensitive information is shared. Such meetings are standard practice for maintaining institutional engagement and transparency.

Meeting scheduled for Monday, February 16, 2026, starting at 10:00 A.M. IST
Event hosted by Spark Capital involving Group and 1x1 meeting formats
In-person meetings to be held in Mumbai with various institutional participants
Company confirms no Unpublished Price Sensitive Information (UPSI) will be disclosed

💡 This is a routine investor relations update and requires no immediate action. Investors may look for any subsequent investor presentations or transcripts that might be uploaded to the exchanges following the event.

Tarsons Products Releases Audio Recording of Q3 FY26 Earnings Conference Call

🟡 NEUTRAL ⭐ 3/10

EARNINGS 📅 06 Feb 2026, 08:17 PM

Tarsons Products Limited has officially released the audio recording of its investor conference call held on February 6, 2026. The call addressed the company's financial performance for the third quarter and nine months ended December 31, 2025. This routine disclosure allows investors to hear management's perspective on the latest unaudited financial results. A written transcript of the discussion is expected to be filed with the stock exchanges and uploaded to the company website shortly.

Audio recording for Q3 FY26 earnings call made available on February 6, 2026.
Covers financial performance for the nine-month period ended December 31, 2025.
Link to the recording is hosted on the company's official investor relations page.
Transcript of the discussion will be provided to BSE and NSE in due course.

💡 Investors should listen to the call or review the upcoming transcript to gauge management's commentary on revenue growth and margin sustainability for the remainder of FY26.

Tarsons to Infuse EUR 3M in Singapore Subsidiary and Appoints New Independent Director

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 06 Feb 2026, 12:45 PM

Tarsons Products Limited has approved an equity infusion of EUR 3 million into its wholly-owned Singapore subsidiary, Tarsons Life Science Pte. Ltd., to fund operational expenses and loan repayments. The board also announced the appointment of Mr. Vinesh Mohan Kriplani, a seasoned M&A and tax expert from the Poonawalla Group, as an Independent Director for a five-year term. This follows the resignation of Mr. Girish Paman Vanvari from the board and its committees. The capital infusion into the Singapore entity is scheduled to be completed in quarterly tranches by March 2027.

Approved equity infusion of EUR 3 million into Singapore-based subsidiary Tarsons Life Science Pte. Ltd.
Capital infusion to be completed in quarterly tranches on or before March 31, 2027.
Appointed Mr. Vinesh Mohan Kriplani, a veteran with 29+ years of experience in M&A and taxation, as Independent Director.
Mr. Girish Paman Vanvari resigned as Independent Director and Chairperson of Audit and Risk committees.
The Singapore subsidiary reported nil turnover for the financial years 2023-24 and 2024-25.

💡 Investors should monitor the strategic utilization of the EUR 3 million infusion in the Singapore subsidiary, which is currently a non-operating entity. The addition of a high-profile M&A expert to the board is a positive sign for future corporate governance and strategic growth.

Tarsons Q3FY26 Revenue up 13% to ₹108 Cr; Adjusted Cash PAT grows 39% YoY

🟡 NEUTRAL ⭐ 7/10

EARNINGS 📅 06 Feb 2026, 12:41 PM

Tarsons Products reported a 12.8% YoY growth in consolidated revenue for Q3FY26, reaching ₹107.9 crores. While EBITDA grew by 6.3% to ₹31.5 crores, the bottom line (Adjusted PAT) for 9MFY26 saw a 41.4% decline due to high depreciation and finance costs from new facility capitalizations. However, Adjusted Cash PAT showed robust growth of 38.6% for the quarter, indicating strong underlying cash generation. The company expects its major capacity expansions at Panchla and Amta to be commissioned in Q4 FY26, which should drive future revenue.

Consolidated Q3FY26 Revenue rose 12.8% YoY to ₹107.9 crores.
Adjusted Cash PAT (PAT + Depreciation) grew 38.6% YoY to ₹31.4 crores in Q3FY26.
9MFY26 EBITDA margins improved to 27.7% from 26.3% YoY.
Consolidated 9MFY26 revenue mix stands at 52% Domestic and 48% Overseas.
Final phase of capacity expansion is on track for commissioning in Q4 FY26.

💡 The stock is currently in a high-capex phase where accounting profits are suppressed by depreciation; investors should monitor the revenue scale-up from new plants in FY27.

Tarsons to Infuse EUR 3M in Singapore Subsidiary; Announces Board Leadership Changes

🟡 NEUTRAL ⭐ 6/10

BOARD_MEETING 📅 06 Feb 2026, 12:39 PM

Tarsons Products Limited has approved an additional equity infusion of EUR 3 million into its Singapore-based wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., to fund operational expenses and loan repayments. The company also announced the resignation of Mr. Girish Paman Vanvari, an Independent Director who chaired the Audit and Risk committees, citing personal commitments. He is replaced by Mr. Vinesh Mohan Kriplani, a seasoned tax and M&A expert with 29 years of experience, including senior roles at Serum Institute and EY. Consequently, the board has reconstituted its Audit, Risk Management, and Nomination & Remuneration committees effective February 6, 2026.

Approved EUR 3 Million equity infusion in Singapore subsidiary Tarsons Life Science Pte. Ltd.
Resignation of Mr. Girish Paman Vanvari as Independent Director and Audit Committee Chairperson.
Appointment of Mr. Vinesh Mohan Kriplani as Additional Independent Director for a 5-year term.
Capital infusion in the subsidiary to be completed in quarterly tranches by March 31, 2027.
Reconstitution of key board committees including Audit, Risk Management, and NRC.

💡 Investors should monitor the strategic utilization of the EUR 3 million infusion in the Singapore entity and observe if the new board composition brings shifts in governance or M&A strategy. The transition appears orderly with a highly qualified replacement for the outgoing director.

Tarsons Products to Infuse EUR 3 Million in Singapore Subsidiary and Appoints New Director

🔵 WATCH ⭐ 7/10

BOARD_MEETING 📅 06 Feb 2026, 12:34 PM

Tarsons Products Limited has approved an equity infusion of EUR 3 million into its Singapore-based wholly-owned subsidiary, Tarsons Life Science Pte. Ltd., to fund loan repayments and operational expenses. The board also announced the appointment of Mr. Vinesh Mohan Kriplani, a veteran tax and M&A expert with 29 years of experience, as an Independent Director for a five-year term. Simultaneously, Mr. Girish Paman Vanvari has resigned from his position as an Independent Director due to personal commitments. These changes have led to a reconstitution of the company's Audit, Risk Management, and Nomination committees.

Approved EUR 3 million (approx. ₹27 crore) equity infusion in Singapore subsidiary to be completed by March 2027.
Appointment of Mr. Vinesh Mohan Kriplani, former Senior Partner at EY India, as an Additional Independent Director.
Resignation of Mr. Girish Paman Vanvari as Independent Director and Chairperson of the Audit Committee.
Released unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025.
Reconstitution of Audit, Nomination and Remuneration, and Risk Management Committees effective February 06, 2026.

💡 Investors should review the detailed Q3 FY26 financial results to assess operational performance while monitoring the strategic utility of the Singapore SPV. The addition of a high-profile M&A and tax expert to the board suggests a continued focus on corporate governance and potential international growth.

View All TARSONS Announcements on Live Market Tracking →

💰 Financial Performance

Revenue Growth by Segment

Consolidated revenue grew 32.4% YoY to INR 392.41 Cr in FY25. Standalone revenue grew 13.3% YoY to INR 314.18 Cr. H1 FY26 standalone revenue grew 4.7% YoY to INR 151.8 Cr.

Geographic Revenue Split

Domestic market remains the primary revenue driver with expanding market share. International operations, specifically the Nerbe acquisition in Germany, contributed INR 80 Cr (approximately 20.4% of consolidated revenue) in FY25.

Profitability Margins

Standalone Gross Margin improved to 72.2% in H1 FY26 from 71.7% YoY. Standalone PAT Margin declined to 6.7% in H1 FY26 from 13.4% YoY due to higher depreciation and finance costs.

EBITDA Margin

Standalone EBITDA Margin improved by 390 bps to 31.9% in H1 FY26. Consolidated EBITDA (excluding forex/other income) was INR 110.73 Cr in FY25.

Capital Expenditure

Invested INR 150 Cr in the Amta facility. The new Panchla facility was capitalized in FY26, leading to accelerated depreciation of INR 37.9 Cr in H1 FY26.

Credit Rating & Borrowing

CARE Ratings reaffirmed the credit rating on June 20, 2025. Consolidated finance costs rose 91.6% YoY to INR 19.39 Cr in FY25 due to expansion-related debt.

⚙️ Operational Drivers

Raw Materials

Plastic resins and granules (polypropylene/polyethylene) used for labware consumables represent the primary raw material cost.

Capacity Expansion

Panchla facility (newly capitalized) and Amta facility (INR 150 Cr investment). Full capacity utilization is expected over the next 3 to 5 years with a ramp-up starting from FY27.

Raw Material Costs

Standalone Cost of Goods Sold (COGS) was INR 42.3 Cr in H1 FY26, representing 27.8% of revenue.

Manufacturing Efficiency

Operating leverage is expected to improve margins as the Panchla facility ramps up from FY27 onwards.

Logistics & Distribution

Distribution costs are being streamlined through centralized fulfillment; specific % of revenue not disclosed.

📈 Strategic Growth

Expected Growth Rate

14.90%

Growth Strategy

Achieving growth through the strategic acquisition of the Nerbe group to penetrate European markets, ramping up the new Panchla facility from FY27 to leverage scale, and launching new plastic labware products to replace traditional glass labware.

Products & Services

Consumables (pipette tips, centrifuge tubes), reusables, and benchtop equipment used in research, academia, and diagnostics.

Brand Portfolio

Tarsons, Nerbe.

New Products/Services

Expansion in high-quality plastic labware consumables designed to replace glass alternatives in research laboratories.

Market Expansion

Deepening presence in European markets via German subsidiaries Nerbe R&D GmbH and Nerbe Plus GmbH.

Market Share & Ranking

Leading plastic labware manufacturing company in India; expanding domestic wallet share.

Strategic Alliances

Acquisition of the Nerbe group (Germany) for approximately INR 98 Cr to enhance global footprint.

🌍 External Factors

Industry Trends

Industry-wide shift from glass to plastic labware consumables driven by research efficiency and safety; market growing due to increased life science investments.

Competitive Landscape

Competition from both established global players and unorganized local manufacturers.

Competitive Moat

Durable advantages include strong brand equity built over decades, manufacturing scale, and ISO 9001/13485 certifications which act as entry barriers.